Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients

Emori, Christini Takemi; Perez, Renata de Mello; Matos, Carla; Uehara, Silvia Naomi de Oliveira; Pereira, Patrícia da Silva Fucuta; Feldner, Ana Cristina de Castro Amaral; Carvalho-Filho, Roberto José de; Silva, Ivonete Sandra de Souza e; Silva, Antônio Eduardo Benedito; Ferraz, M.L.G.

doi:10.1016/j.bjid.2014.06.004

Cited by 10 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral replication and reactivation can develop in HBV (+) Rtx recipients due to immunosuppressive drugs and this can result in many liver pathologies, such as liver cirrhosis and liver failure (1,9,10,23,28,29). Acute viral hepatitis develops more often in patients who are HbsAg(+) (30). Some studies have revealed the correlation between the preoperative viral load and the progression of the liver complications and hepatocellular faiure after Rtx (9,10).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Yılmaz

Çetinkaya

Akbaş

et al. 2016

International Surgery

View full text Add to dashboard Cite

Abstract:Aim: Our aim was to compare the short and long term clinical outcomes of HbsAg(+) renal transplant recipients with HbsAg(-) recipients. Patients and Methods: Two hundered and four patients who underwent renal transplantation in our center between 2001 and 2014 were included in the study. The patients were divided into two groups. Group 1: HbsAg(-) group (n=136) and Group 2: HbsAg(+) group (n=68). There was no significant difference between the groups in terms of lymphocyte cross matches, numbers of mismatches, immunosuppressive treatment protocols and induction treatments. In HbsAg(+) group, 51 patients were HBV DNA(+), 64 patients were HbeAg(-) and 4 patients were HbeAg(+). Fifty-seven (83.8%) patients were treated with Lamivudine, 4 (5.9%) patients with Entecavir and 7 (10.3%) patients with Tenofovir for Hepatitis B infection. Graft and patient survival rates, graft functions, acute hepatitis rates, acute rejection rates and other clinical outcomes of the groups were compared. Results: Demographic data and immuologic risk profiles of the groups were similar. Acute rejection rates, graft survival rates and patient survival rates were similar. Acute hepatitis rates, glomerular filtration rates on the last controls and delayed graft function rates were higher in Group 2, while chronic allograft disfunction and new onset Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporationdiabetes mellitus after transplantation (NODAT) rates were similar between the groups. Conclusion: Our study revealed that, graft and patient survival and acute rejection rates were similar between HbsAg(+) and HbsAg(-) recipients, while acute hepatitis rate was higher in HbsAg(+) recipients. Results: Demographic data and immuologic risk profiles of the groups were similar. Acute rejection rates, graft survival rates and patient survival rates were similar. Acute hepatitis rates, glomerular filtration rates on the last controls and delayed graft function rates were higher in Group 2, while chronic allograft disfunction and new onset diabetes mellitus after transplantation (NODAT) rates were similar between the groups. Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Conclusion:Our study revealed that, graft and patient survival and acute rejection rates were similar between HbsAg(+) and HbsAg(-) recipients, while acute hepatitis rate was higher in HbsAg(+) recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Yılmaz

Çetinkaya

Akbaş

et al. 2016

International Surgery

View full text Add to dashboard Cite

show abstract

“…Viral replication and reactivation can develop in HBV (+) RTR because of immunosuppressive drugs, and this can result in many liver pathologies, such as cirrhosis and liver failure . Acute viral hepatitis develops more often in patients who are HBsAg(+) . Some studies have revealed the correlation between the preoperative viral load and the progression of liver complications and hepatocellular failure after RTx .…”

Section: Discussionmentioning

confidence: 99%

Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(−) donors

Yılmaz

Aliosmanoglu

Erbiş

et al. 2016

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…This occurrence is observed with higher frequency in patients with HBsAg+ and those who are previously infected (HBsAg-and total antiHBc+, with or without antiHBs). The condition is characterized by a rapid increase in aminotransferases, followed by hepatic decompensation and death [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Reactivation in HBsAg Negative Renal Transplant Patients with Evidence of Previous HBV Infection: A Not Neglectable Occurrence

Ferraz¹,

Medina‐Pestana²,

Gama³

et al. 2022

OBM Transplant

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is frequent among patients with chronic kidney disease (CKD). HBV reactivation after kidney transplant (KT) is more common in patients with HBsAg+; however, it can also occur in previously infected individuals, particularly those with HBsAg negative and total antiHBc positive (HBsAg-/antiHBcT+). However, reactivation in this population has scarce and conflicting data. This study aimed to assess the reactivation risk in KT recipients with previous HBV infection (antiHBcT+). A retrospective cohort study was conducted, including patients with KT between January 1993 and December 2012 with HBsAg+ (G1) and with previous HBV infection (antiHBcT+) (G2). A total of 10,493 transplants were performed in this period. A total of 203 patients were included (122 HBsAg+ and 81 HBsAg-/anti-HBcT+). The reactivation of infection occurred in 24.6% (30/38) patients and 9.8% (8/30) in G1 and G2, respectively. Detectable HCV RNA, indicating HCV coinfection, was the only variable related to reactivation in patients with antiHBcT+, protecting its occurrence (p: 0.001). In conclusion, reactivation of HBV infection in KT recipients with the previous infection, occurring in approximately 10% of cases, should be considered. Complete HBV serology is recommended before KT, and patients with HBsAg-/anti-HBcT+ should be monitored after the procedure. Prophylaxis may be indicated when adequate follow-up is not feasible. HCV coinfection appears to be a protective factor for reactivation.

show abstract

Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients

Abstract: Acute exacerbation was a frequent and severe event in HBV-infected renal transplant patients. Prophylactic/preemptive therapy with antiviral drugs should be indicated for all HBsAg-positive renal transplant patients.

Cited by 10 publications

References 23 publications

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(−) donors

Hepatitis B Reactivation in HBsAg Negative Renal Transplant Patients with Evidence of Previous HBV Infection: A Not Neglectable Occurrence

Contact Info

Product

Resources

About